Bluejay Diagnostics (NASDAQ:BJDX) Announces Quarterly Earnings Results

Bluejay Diagnostics (NASDAQ:BJDX) issued its quarterly earnings data on Wednesday. The company reported ($1.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3,520.00) by $3,518.88, FiscalAI reports.

Bluejay Diagnostics Trading Down 1.9%

NASDAQ BJDX traded down $0.02 on Wednesday, hitting $1.05. 297,937 shares of the company were exchanged, compared to its average volume of 2,516,029. The firm has a 50 day moving average of $2.31 and a two-hundred day moving average of $2.24. The company has a market cap of $1.08 million, a P/E ratio of -0.09 and a beta of 0.89. Bluejay Diagnostics has a 1-year low of $0.83 and a 1-year high of $16.68.

Analyst Upgrades and Downgrades

BJDX has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Wednesday, June 24th. Wall Street Zen upgraded shares of Bluejay Diagnostics to a “sell” rating in a research note on Saturday, July 18th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Insider Buying and Selling at Bluejay Diagnostics

In related news, major shareholder Financial Lp Hrt bought 64,047 shares of Bluejay Diagnostics stock in a transaction dated Thursday, July 9th. The shares were bought at an average cost of $1.51 per share, for a total transaction of $96,710.97. Following the completion of the transaction, the insider owned 126,993 shares of the company’s stock, valued at approximately $191,759.43. This trade represents a 101.75% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC bought a new stake in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics at the end of the most recent quarter. Institutional investors own 18.47% of the company’s stock.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.